1 BTC
=
- USD
GRAIL, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About GRAIL, Inc. Common Stock
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Market Statistics
Trading Metrics
How to Buy GRAL
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy GRAL
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesGrail stock rose 11.4% this week as Wall Street analysts warm to its risk/reward proposition. Despite the company's Galleri multi-cancer early detection test failing to meet its primary endpoint in February, analysts believe follow-up trial data could validate efficacy. TD Cowen upgraded the stock, and Guggenheim reiterated a buy rating with a $130 price target, suggesting potential FDA approval and Medicare coverage pathways.
Robbins Geller Rudman & Dowd LLP has launched an investigation into GRAIL, Inc. for potential violations of U.S. federal securities laws. The investigation follows GRAIL's announcement on February 19, 2026, that its NHS-Galleri trial failed to meet its primary endpoint of statistically significant Stage III-IV cancer reduction, causing the stock price to fall significantly.
The Supreme Court ruled 6-3 that President Trump's sweeping global tariffs were unconstitutional, finding that the International Emergency Economic Powers Act does not authorize the president to impose tariffs without clear congressional authorization. The decision triggered a sharp rally across U.S. equities, with 10 stocks posting significant gains following the ruling that invalidates tariffs that had reached up to 145% on some products.
U.S. stock futures rose on Friday ahead of Q4 GDP data and PCE inflation gauge releases. Markets are pricing in a 94% likelihood of unchanged Fed rates in March. Notable movers include Copart missing earnings expectations, Comfort Systems raising dividends, Grail plunging 47% on weak earnings, Candel Therapeutics declining on stock offering announcement, and Dropbox falling despite beating earnings. Wells Fargo strategist recommends leaning into growth-sensitive sectors like Financials and Industrials rather than defensive positioning.
Grail's stock surged 13% following optimism about its Galleri multi-cancer early detection test. The company projects 22-32% revenue growth for 2026 and plans to submit for FDA premarket approval in Q1 2026, which could unlock medical coverage and boost adoption. With $904 million in cash and improving burn rates, management believes it has runway through 2030.